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Abstract
Purpose To report the usage of PGD for α-thalassaemia
with the --
SEA genotype.
Method A PGD protocol using fluorescent gap PCR was
performed for 51 cycles on 43 couples with the --
SEA
genotype. Allele drop-out and amplification failure rates
were retrospectively analyzed.
Results A total of 472 embryos were biopsied. Amplification
was achieved in 390 blastomeres, accounting for an
amplification rate of 82.6%. In total, 120 wild-type, 94
heterozygotes and 140 homozygous mutant embryos
were diagnosed. The successful diagnosis rate was
75.0%. The ADO rate in 49 blastomeres from six
donated embryos was 16.4%. One hundred and fifty
four embryos were transferred, resulting in 25 clinical
pregnancies with an implantation rate of 24.0%.
Conclusions Single-round fluorescent gap PCR is a feasible
and effective strategy in the PGD for α-thalassaemia with
the --
SEA genotype.
Keywords Preimplantationgeneticdiagnosis.
α-thalassaemia.FluorescentPCR
Introduction
Thalassaemia is the most common monogenetic hemoglobin
disease in Southeast Asia and southern China. Deficiency of
the α-globin chains results in α-thalassaemia. Affected
homozygotes of α-thalassaemia, Hb Bart’s hydrops fetalis,
die either in utero in late gestation or within a few minutes
after birth. Mothers carrying such hydropic fetuses are likely
to develop severe hypertension, eclampsia and obstetric
hemorrhage [1]. In southern China, the carrier rate of
α-thalassaemia is 8.53% [2]. Among various genotypes,
Southeast Asia deletion (--
SEA) is the most commonly
observed, with incidence rates ranging from 72.87% to
82.87% [3, 4]. For this autosomal recessive disorder,
carriers of one mutant alleleare asymptomatic, but
couples who are both carriers of the --
SEA mutation
(--
SEA/αα) run a 25% risk of having a hydropic fetus. For
this reason, prenatal diagnosis in pregnancies has been
advocated by the Chinese government for a number of years.
Preimplantation genetic diagnosis (PGD) is considered
as an alternative for prenatal diagnosis. Many reports of
successful PGD performed for β-thalassaemia have been
published [5, 6]; however, PGD for α-thalassaemia remains
poorly studied [7–10]. To the best of our knowledge, only
three live births have been reported [9, 10], including two
by our group. The reason may be partly attributable to the
fact that this regional disease is mainly found in econom-
ically less developed Southeast Asian countries. Previ-
ously, we established a fluorescent gap PCR protocol for
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we report our clinical application of 51 PGD cycles during
a 4-year period.
Materials and methods
Patients
BetweenJanuary2004andDecember 2007,51cyclesofPGD
were performed for 43 couples with the --
SEA genotype
(deletion of 2 α-globin genes in cis). Thirty-five couples
underwent a single PGD cycle, and the remaining eight
couples underwent two PGD cycles. Twenty-nine couples
had a history of abnormal pregnancies. A total of 68 hydropic
fetuses diagnosed by prenatal diagnosis as the --/-- genotype
were selectively terminated in these couples. The subsequent
analysis showed both parents were carriers of the --
SEA
genotype (--
SEA /αα). In addition, fourteen couples without
abnormal pregnancy history were infertile, and in each case
bothpartnerswerediagnosedascarriersofthe --
SEA genotype
during routine genetic screening prior to IVF in our center.
Ethnical approval was obtained for this study from the
Ethnical Board of Sun Yat-sen University.
Methods
Ovarian stimulation and embryo culture
Ovarian stimulation was performed by a desensitizing long
protocol using a gonadotrophin-releasing hormone analog
(Daphiline Beaufour IPSEN, France) in association with
recombinant follicle stimulating hormone (Gonal-F, Laborato-
ries Serono SA, Switzerland) and human chorionic gonado-
trophin (Profasi, Laboratories Serono SA, Switzerland).
Oocyte retrieval was carried out by ultrasound-guided punc-
ture 36 h after human chorionic gonadotrophin administration.
Standard intracytoplasmic sperm injection (ICSI) was
performed on metaphase II oocytes [11]. After ICSI,
oocytes were cultured in HTF medium (SAGE BioPharma,
US) for 3 days.
Embryo biopsy
In PGD using blastomere biopsy, embryos with at least five
blastomeres were biopsied in Ca
2+/Mg
2+ free medium
under oil (SAGE, BioPharma, US) on the morning of day
3 after oocyte retrieval. Partial zona dissection (PZD) was
performed to make a split in the zona pellucida. A sampling
Fig. 1 Eletrophoretogram of PCR products for PGD. The top, second and third lanes are the affected, heterozygote, and normal samples,
respectively. The bottom lane shows the heterozygote sample with preferential amplification in affected allele
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withdraw single cells. After biopsy, embryos were rinsed
carefully and cultured in blastocyst medium (SAGE
BioPharma, US) until transfer [9].
PGD for α-thalassaemia
The biopsied blastomeres were washed three times in
sterile phosphate buffer saline (PBS) and transferred into
a 0.2 mL Eppendorf tube containing a lysis solution of
0.5 μL 10XPCR Buffer, 0.5 μL1 %T w e e n - 2 0 ,0 . 5μL
1% Triton-100, 3.5 μLH 2O, and 0.05 μL proteinase K
(20 mg/mL) as described previously [9]. For each biopsied
blastomere, a blank control was prepared from the final
PBS cell wash drop. The positive controls were prepared
with 10 pg of purified DNA from the patients.
Biopsiedblastomereswerelysedbyincubatingat45°Cfor
15 min and inactivated by heating to 96°C for 20 min. The
amplification involved the use of three α-thalassaemia SEA
primers.TheS1andS3primersflanktheSEAdeletion,while
the S2 primer anneals within the deleted area [12]. The
sequence of S1 is 5′-gtgttctcagtattggagggaa-3′. The S2 and S3
primers had the sequence of 5′-FAM-gacacgcttccaatacgctta-3′
and 5′-HEX-ctactgcagccttgaactcc-3′, and were labeled with
blue and green fluorescent dye, respectively. In wild-type
samples,the S1 and S2 primers amplified a product of282bp.
However, in mutant samples, the S1 and S3 are brought into
close proximity by deletion of the intervening sequence and
were able to amplify a product of 178 bp (Fig. 1).
Aliquots of 50 μl PCR master mix containing 5 μl lysis
solution, 4.5 μl 10XPCR neutralizing buffer, 1.5 μl
50 mmol/L MgCl2, 1 μl each 10 mmol/L dNTP, 2.0 μl
each of primers S1,S2 and S3, 1.5U AmpliTap DNA
polymerase(ABI) were added to reaction tubes. PCR
reactions were performed using a Perkin Elmer Cetus
9700 PCR machine. The program used was 2 min initial
denaturation at 96°C followed by 45 s denaturation at 96°C
for the first 10 cycles and 94°C for the 40 remaining cycles.
Annealing and elongation cycles were performed for 45 s at
60°C and 60 s at 72°C, respectively. The PCR reaction was
terminated by 7 min at 72°C. PCR products were then
analyzed on an ABI 3100 Advant genetic analyzer.
Only embryos diagnosed as wild-type or heterozygous
would be recommended as suitable for embryo transfer.
Following genetic diagnosis, one to three suitable embryos
wereselectedonmorphologicalcriteriaandtransferredonday
4 with cryopreservation of any remaining suitable embryos.
Results
A total of 51 biopsy cycles were carried out for 43 couples,
with an average age of the female partner at 30.7±3.5. An
average of 17.3 oocytes was retrieved per cycle with a
fertilization rate of 70.9%.
The embryo biopsy procedure was successfully performed
in all cases. A total of 472 embryos were biopsied, of which
390 were successfully amplified with an amplification rate of
82.6%. Diagnosis of 36 embryos yielded ambiguous results:
24 showed nonspecific amplification products along with
target gene products, and eight exhibited contamination in
blank controls. Overall, 120 normal homozygous (wild-type)
embryos, 94 heterozygous carrier embryos and 140 abnormal
homozygous embryos were diagnosed respectively, accounting
for a total diagnostic rate of 75.0% (354/472).
Preferential amplification was detected in 18 blastomeres.
In the re-analysis of 49 blastomeres from six discarded
heterozygous embryos, 39 blastomeres were successfully
amplified, of which 9 showed allele drop-out (ADO),
indicative of an ADO rate of 16.4%[9/(49+6)].
A total of 154 embryos including 101 wild-type embryos
and 53 heterozygous embryos were transferred, resulting in
25 clinical pregnancies with an implantation rate of 24.0%
(37/154). The 25 clinical pregnancies included 12 single-
tons, six twins, four triplets and one tubal pregnancy. Two
singleton miscarriages occurred before 12 weeks of
pregnancy. One fetus was diagnosed as a 13 trisomy by
prenatal diagnosis, and selective termination was performed
at 20 weeks of gestation. Spontaneous fetal reduction
occurred in one twin and one triplet pregnancies. Fetal
reduction was performed in the three remaining triplets
according to the official regulation. After fetal reduction,
routine ultrasound at 13 weeks of gestation revealed one
case suffered fetal edema in one of the two remaining
fetuses; consequently, a second fetal reduction was per-
formed. The chromosomal analysis of fetal tissue showed a
45,XO karyotype. In summary, 27 healthy babies were
born. Prenatal diagnosis showed 17 were wild-type and 10
were heterozygous for the α-globin loci. No misdiagnosis
was observed.
Discussion
Prenatal diagnosis for α-thalassaemia has been proven to
be an effective strategy for combating severe obstetric
complications in mothers carrying hydropic fetus in late
gestation and is widely used in southeast China.
However, once diagnosed, the decision to terminate an
affected pregnancy is sometimes difficult. Furthermore,
repeated termination of affected pregnancies will also
cause both physical and mental trauma to mothers. In
this study, a total of 68 hydropic fetuses were selectively
terminated in 29 couples. The establishment of a PGD
protocol offers an opportunity to avoid the adverse con-
sequences of pregnancy termination, since abnormal embryos
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fertility problems may consider transfer unaffected embryos
by PGD when receiving IVF treatment.
Gap PCR is a reliable method for prenatal diagnosis of
α-thalassaemia [12]. Previously, semi-nested or nested
second round PCR has been adopted in the PGD for
α-thalassaemia to ensure specific amplification [7]. The
detection sensitivity for small amounts of PCR products
was improved by the application of fluorescent labeled
primers and the analysis of amplified PCR products by a
genetic analyzer. In the study by Chan et al. [10], multiplex
fluorescent gap-PCR was performed to include 34 ampli-
fication cycles in the first round and 23 cycles in the second
round PCR. Moreover, they estimated the ADO and PCR
failure rate at 10.2% and 12.7%, respectively, lower than
the 24.9% reported previously [7].
Inthepresentstudy,theuseof single-roundfluorescentPCR
with 50 cycles was sufficient to amplify PCR products for the
analysisonthegeneticanalyzer.TheADOandPCRfailurerate
was 16.4% and 17.4%, respectively, only slightly higher than
those from two-round PCR by Chan et al. [10]. Furthermore,
single-round fluorescent PCR significantly reduces the risk
of contamination and is much less laborious to perform.
ADO and PCR failure rates are the main parameters for
the evaluation of feasibility of a PGD strategy. ADO is
considered as the main cause of misdiagnosis in PGD [13,
14]. In the current study, the ADO rate was estimated from
the re-analysis of discarded embryos. However, chromo-
some mosaicism in discarded embryos may affect the ADO
rate. In fact, the ADO rate can be deduced from the ratio of
heterozygote embryos. Only 26.6% (94/354) embryos were
diagnosed as the heterozygote embryo, which was signif-
icantly lower than the expected ratio of 50%. In the case of
heterozygote embryos, ADO for the normal allele may lead
to misdiagnosis as the homozygous mutant embryo;
conversely, ADO of the mutant allele may cause misdiagno-
sis as the normal homozygote embryo. Collectively, such
diagnostic deficiencies will lead to a lower ratio of heterozy-
gote embryos and a reduced number of embryos available for
transfer in the present study. Nevertheless, since α-
thalassaemia is an autosomal recessive disease, the presence
of the normal allele in the transferred embryos should offset
any adverse consequence due to ADO in the mutant allele.
Contamination in single-cell PCR from exogenous DNA
can not be reliably excluded with currently available
methods [15]. To minimize such risk, we employed
dedicated airborne manipulator for PGD, and the biopsy
area for clinical application was physically separated from
tubing and pre-PCR areas. Post-PCR analysis was per-
formed in a distinct space from pre-PCR steps. Blastomere
tubing and PCR preparation were carried out in a clean
laminar flow cabinet. Although eight blastomeres exhibited
contamination in blank controls and 24 showed nonspecific
amplification products along with target gene products in
the present study, the vast majority of reactions produced
clear results devoid of any contamination.
In summary, single-round fluorescent gap PCR is
a feasible and effective strategy in the PGD for
α-thalassaemia. However, the ADO and PCR failure
rates remain as major concerns for diagnostic accuracy
and efficiency. Analogous to the PGD for Duchenne
muscular dystrophy via multiple displacement amplifi-
cation recently published by our group [16], the closely
linked STR locus will be analyzed in parallel in future
studies to reduce the risk of misdiagnosis and omission of
heterozygotes due to ADO in the normal allele. Finally,
blastocyst biopsy, which provides more trophectoderm cells
for diagnosis, will also be considered to overcome the
inherent sensitivity limitation of single-cell PCR [17].
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